Omeros (OMER): Reiterating $21 PT On Solid Prelim Phase II Data - Cantor Fitzgerald

October 17, 2016 9:28 AM EDT
Get Alerts OMER Hot Sheet
Price: $9.05 --0%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 29 | New: 23
Trade OMER Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst, Elemer Piros, reiterated his Buy rating on Omeros Corp. (NASDAQ: OMER) after the company reported initial positive results from its Phase 2 trial with OMS721, a complement inhibitor, in six patients across three separate renal diseases.

In two out of the three nephropathy conditions tested, there are encouraging signals of efficacy for OMS721. Nothing is approved and nothing has really worked in these steroid-dependent populations. These patients, with >1,000mg protein in their urine, are headed to end stage renal disease and a transplant.

It is important to note, that the successful data was in six patients. No change to $21 price target.

price target of $21.00

For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.

Shares of Omeros Corp. closed at $7.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cantor Fitzgerald

Add Your Comment